Novel CAR-T therapy achieves positive results in a high proportion of patients with a refractory type of lymphoma

**CAR-T Therapy Shows High Efficacy in Patients with Refractory CD30+ Lymphoma**

Researchers have reported promising outcomes for a novel CAR-T cell therapy targeting the CD30 protein in patients with refractory CD30+ lymphoma. The therapy, known as HSP-CAR30, was developed through a collaboration between the Sant Pau Research Institute (IR Sant Pau), Sant Pau Hospital, and the Josep Carreras Leukemia Research Institute. Early findings indicate that the treatment achieved positive results in a significant proportion of patients who had not responded to previous therapies.

The research team focused on utilizing chimeric antigen receptor T-cell (CAR-T) technology to specifically target the CD30 protein, which is commonly expressed in certain types of lymphoma. This approach aims to enhance the immune system’s ability to identify and destroy cancer cells. The study highlights HSP-CAR30’s potential as an effective option for individuals with limited treatment alternatives due to resistance or relapse after standard therapies. Further details regarding patient response rates and clinical outcomes are expected as research progresses.

Newsflash | Powered by GeneOnline AI

Source: https://medicalxpress.com/news/2025-04-car-therapy-positive-results-high.html

Related posts:

Pharmacists Offer MTM Consultations, Contributing Clinical Recommendations to Healthcare Teams. Genetic factors highlight the many ways health and height are linked STAT’s D.C. Diagnosis Newsletter Delivers Twice-Weekly Updates on Health Policy and Politics **Study Shows 3 Months of Exercise Improves Memory Recall by 20%**

Author

Mark Chiang

紐約 NYU Computer Science 碩士 紐澤西 UMDNJ Biomedical Informatics 博士 中研院博士後 台灣大學博士後